Odefsey: New HIV Combination Pill Is More Gentle on Bones, Kidneys

March 1, 2016


The FDA has approved a new once-daily drug regimen for the treatment of HIV. Odefsey, by Gilead Sciences, is composed of emtricitabine (200 mg), rilpivirine (25 mg) and tenofovir alafenamide (25 mg).

Odefsey contains the same drugs as Complera, except it replaces disoproxil fumarate (TDF) with tenofovir alafenamide (TAF). TAF is a prodrug of tenofovir that delivers high antiviral efficacy at a much lower dose than TDF. The lower dose of TAF that can be used to treat HIV means that it has a better safety profile -- and is easier on the kidneys and bones -- than TDF.

"As people are living longer with HIV, there is an increasing need to develop new treatments that are tolerable and help address long-term health for patients," said John C. Martin, Ph.D., chairman and chief executive officer of Gilead Sciences. "Odefsey's safety, efficacy and tolerability profile offers a new treatment option to support the needs of a range of patients and represents Gilead's commitment to innovation in the field of HIV."

This excerpt was cross-posted with the permission of Read the full article.

This article was provided by BETA. Visit their website at

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.